Skip to main content

HIV Dynamics

We work closely with the Rakai Health Sciences Program and other collaborators to study HIV transmission in sub-Saharan Africa

We work on a variety of epidemiological studies focused on HIV transmission dynamics and the impact of prevention interventions. Our research largely takes place in Sub-Saharan Africa but we have also collaborated on domestic initatives.

We closely collaborate with the Rakai Health Sciences Program (RHSP) in Uganda, which is one of the leading HIV research institutions in Sub-Saharan Africa. Rakai, located in Southwest Uganda, is where the first AIDS cases were identified in Eastern Africa and today it remains one of the highest-burden districts in the region with an overall HIV prevalence of ~14%. However, within Rakai there is substantial geographic heterogeneity in HIV prevalence ranging from 9-43% at the community-level. We currently support NIH and BMGF initiatives to understand the role of extremely-high-prevalence communities (i.e. "geographic hotspots") and other key populations within the broader regional epidemic with the overarching goal of informing targeting HIV prevention initiatives under PEPFAR Phase III. Our work with RHSP includes dynamic HIV modelling and viral phylogenetics conducted in collaboration with the PANGEA-HIV consortium and researchers (and friends!) at Oxford University and Imperial College London in the UK.

We also have an iniative supported by the Johns Hopkins Center for AIDS Research/NIH to use network models and viral phylogenetics to inform real-time interventions to prevent HIV among young men who have sex with men in Baltimore City, Maryland.

Updates #HIV

1 year 1 month ago

RT @JustinLessler: Preprint with our look at the literature on #HIV incidencenin sub-Saharan Africa with @KateGrabowski and… https://t.co/6Hj4ac7HU3
4 years 1 month ago

Congratulations to @KateGrabowski and the Rakai team on there important paper on #HIV incidence declines in Rakai in @NEJM
4 years 9 months ago

Congratulations to @katierisher on her exceptional defense of her dissertation today. #HIV
5 years 1 month ago

What can phylogenetics tell us about #HIV transmission? @KateGrabowski and @JustinLessler comment in @TheLancetHIV. https://t.co/b2Pc28yFHG
5 years 1 month ago

RT @KateGrabowski: Congrats to Jess Prodger & Rakai team on new paper looking at inflammation and HIV risk in men! @JHIDDynamics #HIV https://t.co/PFeVseXVtK
5 years 6 months ago

Congrats to @KateGrabowski and the whole RHSP team on the their paper in Lancet HIV. With a commentary no less! https://t.co/cDgxIDYvA7 #HIV
5 years 6 months ago

Congrats to @KateGrabowski, Allison A., Errol F., others on @HopkinsCFAR award to study HIV transmission in Baltimore w/phylogenetics! #HIV

Publications

17 Apr 2021

Regression with interval-censored covariates: Application to cross-sectional incidence estimation

Morrison D, Laeyendecker O, Brookmeyer R

Biometrics, 2021: 10.1111/biom.13472

1 May 2021

The HIV Screening Cascade: Current Emergency Department-Based Screening Strategies Leave Many Patients With HIV Undiagnosed

Mohareb AM, Patel AV, Laeyendecker OB, Toerper MF, Signer D, Clarke WA, Kelen GD, Quinn TC, Haukoos JS, Rothman RE, Hsieh YH

J Acquir Immune Defic Syndr, 2021: 87(1): e167-e169, 10.1097/QAI.0000000000002609

2 Mar 2021

A high prevalence of potential HIV elite controllers identified over 30 years in Democratic Republic of Congo

Berg MG, Olivo A, Harris BJ, Rodgers MA, James L, Mampunza S, Niles J, Baer F, Yamaguchi J, Kaptue L, Laeyendecker O, Quinn TC, McArthur C, Cloherty GA

EBioMedicine, 2021: 65:103258: 10.1016/j.ebiom.2021.103258

20 May 2021

A top scoring pairs classifier for recent HIV infections

Chen A, Laeyendecker O, Eshleman SH, Monaco DR, Kammers K, Larman HB, Ruczinski I

Stat Med, 2021: 40(11): 2604-2612, 10.1002/sim.8920

25 Feb 2021

Validation of the Asante HIV-1 Rapid Recency Assay for Detection of Recent HIV-1 Infections in Uganda

Galiwango RM, Ssuuna C, Kaleebu P, Kigozi G, Kagaayi J, Nakigozi G, Reynolds SJ, Lutalo T, Kankaka EN, Wasswa JB, Kalibbala SN, Kigozi AN, Watera C, Ejang J, Ndyanabo A, Anok AJ, Ssemwanga D, Kibengo FM, Quinn TC, Grabowski M, Chang LW, Wawer M, Gray R, Laeyendecker O, Serwadda D

AIDS Res Hum Retroviruses, 2021: 10.1089/AID.2020.0279

27 May 2020

Impact of Early Antiretroviral Treatment Initiation on Performance of Cross-Sectional Incidence Assays

Klock E, Mwinnya G, Eller LA, Fernandez RE, Kibuuka H, Nitayaphan S, Kosgei J, Moore RD, Robb M, Eshleman SH, Laeyendecker O

AIDS Res Hum Retroviruses, 2020: 36(7): 583-589, 10.1089/AID.2019.0286

18 Feb 2020

Longitudinal Antibody Responses in People Who Inject Drugs Infected With Similar Human Immunodeficiency Virus Strains

Redd AD, Doria-Rose NA, Weiner JA, Nason M, Seivers M, Schmidt SD, Laeyendecker O, Martens C, Bruno D, Keele BF, Raju N, Georgiev IS, Lamers SL, Astemborski J, Kirk GD, Mascola JR, Ackerman ME, Mehta SH, Quinn TC

J Infect Dis, 2020: 221(5): 756-765, 10.1093/infdis/jiz503

18 Feb 2020

Determination of HIV status and identification of incident HIV infections in a large, community-randomized trial: HPTN 071 (PopART)

Eshleman SH, Piwowar-Manning E, Wilson EA, Lennon D, Fogel JM, Agyei Y, Sullivan PA, Weng L, Moore A, Laeyendecker O, Kosloff B, Bwalya J, Maarman G, van Deventer A, Floyd S, Bock P, Ayles H, Fidler S, Hayes R, Donnell D; HPTN 071 (PopART) Study Team

J Int AIDS Soc, 2020: 23(2): e25452, 10.1002/jia2.25452

Pages

Images